SINTX Technologies (SINTX Technologies) Debt-to-EBITDA

: -0.57 (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

Debt-to-EBITDA measures a company's ability to pay off its debt.

SINTX Technologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.56 Mil. SINTX Technologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $3.69 Mil. SINTX Technologies's annualized EBITDA for the quarter that ended in Dec. 2023 was $-7.49 Mil. SINTX Technologies's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.57.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for SINTX Technologies's Debt-to-EBITDA or its related term are showing as below:

SINT' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.94 Med: -0.43 Max: -0.02
Current: -0.64

During the past 13 years, the highest Debt-to-EBITDA Ratio of SINTX Technologies was -0.02. The lowest was -0.94. And the median was -0.43.

SINT's Debt-to-EBITDA is ranked worse than
100% of 428 companies
in the Medical Devices & Instruments industry
Industry Median: 1.225 vs SINT: -0.64

SINTX Technologies Debt-to-EBITDA Historical Data

The historical data trend for SINTX Technologies's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SINTX Technologies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

Get a 7-Day Free Trial

-0.52

-0.35

-0.34

-0.26

-0.64

SINTX Technologies Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial															-0.20	13.02	-0.27	-0.18	-0.57

Competitive Comparison

For the Medical Devices subindustry, SINTX Technologies's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SINTX Technologies Debt-to-EBITDA Distribution

For the Medical Devices & Instruments industry and Healthcare sector, SINTX Technologies's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where SINTX Technologies's Debt-to-EBITDA falls into.

SINTX Technologies Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

SINTX Technologies's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.558	+	3.687)	/	-6.6
	=	-0.64

SINTX Technologies's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.558	+	3.687)	/	-7.492
	=	-0.57

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.

SINTX Technologies (NAS:SINT) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

SINTX Technologies Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of SINTX Technologies's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

SINTX Technologies (SINTX Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » SINTX Technologies Inc (NAS:SINT) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

111A:Germany 111A:Germany

Address

1885 West 2100 South, Salt Lake City, UT, USA, 84119

Website

https://www.sintx.com

SINTX Technologies Inc is a commercial biomaterial company engaged in using its silicon nitride technology platform to develop, manufacture, and sell a range of medical devices. The company derives product revenue primarily from the manufacture and sale of spinal fusion products used in the treatment of spine disorders. It produces silicon nitride for use in commercial products and product candidates in the forms of Solid Silicon Nitride, Porous Silicon Nitride, and Silicon Nitride Powder, among others. It is also engaged in developing wear-and corrosion-resistant implant components for hip and knee arthroplasty.

Executives

David W. Truetzel	director	C/O AMEDICA CORPORATION, 1885 WEST 2100 STREET, SALT LAKE CITY UT 84119
David Francis O'brien	officer: Chief Operating Officer	1885 WEST 2100 SOUTH, SALT LAKE CITY UT 84119
Ty Lombardi	officer: VP Finance	C/O AMEDICA CORPORATION, 1885 W 2100 SOUTH, SALT LAKE CITY UT 84119
Eric A Stookey	director	5677 AIRLINE ROAD, ARLINGTON TN 38002
Gordon Esplin	officer: Vice President, Finance	C/O AMEDICA CORPORATION, 1885 WEST 2100 SOUTH, SALT LAKE CITY UT 84119
Kevin Ontiveros	officer: See Remarks	C/O IMARX THERAPEUTICS INC, 1635 EAST 18TH STREET, TUCSON AZ 85719
Arthur Karl Kipke	10 percent owner	C/O AMEDICA CORPORATION, 1885 WEST 2100 STREET SOUTH, SALT LAKE CITY UT 84119
Jay M Moyes	director, officer: Chief Fnancial Officer
Vytas Rupinskas	officer: SVP, Marketing	C/O AMEDICA CORPORATION, 1885 WEST 1200 STREET, SALT LAKE CITY UT 84119
Eric K. Olson	director, officer: President and CEO	C/O AMEDICA CORPORATION, 1885 WEST 2100 STREET SOUTH, SALT LAKE CITY UT 84119
James P. Abraham	officer: SVP, Global Sales	C/O AMEDICA CORPORATION, 1885 WEST 1200 STREET, SALT LAKE CITY UT 84119
Christopher Whitfield	officer: Chief Commercial Officer	C/O AMEDICA CORPORATION, 1885 WEST 1200 STREET, SALT LAKE CITY UT 84119
Max Link	director	509 MADISON AVE 14TH FL, NEW YORK NY 10022
Kevin L Davis	officer: Chief Operating Officer	9149 SOUTH MONROE PLAZA WAY, SUITE B, SANDY UT 84070
Jeffrey S. White	director	C/O AMEDICA CORPORATION, 1885 WEST 2100 STREET SOUTH, SALT LAKE CITY UT 84119